Bicara Therapeutics (BCAX) awarded inducement grants on February 2, 2026 to two new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 158,900 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $16.76 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on February 2, 2026. One-fourth of the options vest on the first anniversary of the employee’s applicable start date, with the remaining options vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Bicara Therapeutics initiated with an Outperform at Citizens
- BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target
- Maintaining a Buy on Bicara Therapeutics: De‑Risked Phase 3 Path for Ficerafusp Alfa Supports $40 Target and $2.2B Valuation
- Bicara Sets Phase 3 Path for Ficerafusp Alfa
- Bicara Therapeutics announces Phase 3 optimal dose of ficerafusp alfa
